Skip to main content
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 2021 Sep 7;70(12):3709. doi: 10.1007/s00262-021-03040-0

Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL

Sarah B Reusing 1,2, Dan A Vallera 3, Angela R Manser 1, Titus Watrin 2, Sanil Bhatia 2, Martin Felices 4, Jeffrey S Miller 4, Markus Uhrberg 1, Florian Babor 2,
PMCID: PMC8571238  PMID: 34491408

Correction to: Cancer Immunology, Immunotherapy 10.1007/s00262-021-03008-0

The original version of this article unfortunately contained a mistake. Author name Titus Watrin was incorrectly written as Titus Vatrin.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES